The treatment of patients with glioblastoma multiforme (GBM) is conventionally considered to be a palliative venture with no hope of cure. Traditionally, patients are treated with maximal surgical resection based on the premise that, although surgery is not a curative procedure, a major resection provides for a longer survival and better quality of life. Radiotherapy increases the duration of survival, but again is not a curative intervention.The role of chemotherapy, specifically focusing on a foundation of chloroethylating agents such as carmustine (BCNU) or lomustine (CCNU), has been controversial with an equal number of clinicians arguing in favor of or against this treatment. Meta-analysis makes it clear that there is a small increase in median survival associated with the addition of these agents, but a consensus was never reached regarding their use.
read more at http://www.virtualtrials.com/pdf/Friedman.pdf
Monday, 10 March 2008
State-of-the-art Therapy for Glioblastoma Multiforme
Labels:
Brain Cancer